Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
Liquidia Corporation (LQDA)
Last liquidia corporation earnings: 3/11 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA confirmed that the resubmission was a complete, Class 1 response to the previous action letter issued on August 16, 2024, which granted tentative approval of YUTREPIA for both PAH and PH-ILD. The FDA has set a Prescription Drug
Read more
Impact Snapshot
Event Time:
LQDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LQDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LQDA alerts
High impacting Liquidia Corporation news events
Weekly update
A roundup of the hottest topics
LQDA
News
- UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder [Yahoo! Finance]Yahoo! Finance
- Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International ConferenceGlobeNewswire
- Liquidia Co. (NASDAQ: LQDA) had its "outperform" rating re-affirmed by analysts at Scotiabank.MarketBeat
LQDA
Earnings
- 11/13/24 - Beat
LQDA
Sec Filings
- 3/28/25 - Form 8-K
- 3/27/25 - Form EFFECT
- 3/19/25 - Form S-3
- LQDA's page on the SEC website